Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VYGR
Strong SellSinkerVoyager Therapeutics, Inc. · Healthcare · United States · $218M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Voyager Therapeutics, Inc. is a gene therapy company focused on developing treatments for severe neurological diseases, including Parkinson's disease and Huntington's disease. Its proprietary TRACER™ capsid discovery platform aims to enhance gene therapy delivery and efficacy, providing a potential advantage in a rapidly evolving field. Voyager is a clinical-stage biotechnology firm leveraging advanced gene therapy platforms for central nervous system disorders.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.9M | 250.0M | 80.0M | 40.4M | -0.4% | 34.5M | 20.3M | 46.6M | 7.4% |
| EPS | -1.21 | 3.08 | -1.13 | -2.04 | — | -1.81 | -1.70 | -1.28 | — |
| Shares | 38.6M | 44.0M | 54.7M | 59.0M | +52.9% | 61.6M | — | — | — |
| Debt | 23.1M | 20.3M | 43.7M | 36.5M | 16.4% | 32.6M | — | — | — |
| Equity | 59.0M | 236.3M | 299.8M | 196.1M | 49.2% | — | — | — | — |
| Op CF | -12.5M | 77.9M | -15.3M | -132.5M | — | -120.6M | — | — | — |
| Inv CF | -7.3M | -141.6M | -94.9M | 125.4M | — | — | — | — | — |
| Fin CF | 1.1M | 33.6M | 114.0M | 0.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VYGR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VYGR | Voyager Therapeutics, Inc.(you) | $218M | 14 | Strong Sell |
| CHRS | Coherus Oncology, Inc. | $218M | 14 | Strong Sell |
| PEPG | PepGen Inc. | $213M | 14 | Strong Sell |
| ABOS | Acumen Pharmaceuticals, Inc. | $211M | 13 | Strong Sell |
| KROS | Keros Therapeutics, Inc. | $219M | 16 | Strong Sell |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $233M | 14 | Strong Sell |
| NERV | Minerva Neurosciences, Inc. | $231M | 12 | Strong Sell |
| CUE | Cue Biopharma, Inc. | $203M | 16 | Strong Sell |
| SION | Sionna Therapeutics, Inc. | $265M | 14 | Strong Sell |
| ELDN | Eledon Pharmaceuticals, Inc. | $260M | 15 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%